Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMNIRAY: LY4257496 in GRPR-Positive Advanced Solid Tumors
NCT07114601Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2025
- Primary completion
- Apr 2030
- Countries
- 7
01
Overview
Phase 1, open-label trial of LY4257496 in breast cancer, colorectal cancer (CRC), prostate cancer (PCa) and 5 more (5 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Tolerated Dose at 28 days, Dose Limiting Toxicities at 28 days and 1 more. Started Aug 2025; status: recruiting.
02
Drugs
LY4257496
03
Conditions
breast cancercolorectal cancer (CRC)prostate cancer (PCa)endometrial cancer (EC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT07114601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07114601.